Skip to main content
Navigate back to homepage
Open search bar.
Open main navigation menu

Main navigation

  • Study
    UCL Portico statue
    Study at UCL

    Being a student at UCL is about so much more than just acquiring knowledge. Studying here gives you the opportunity to realise your potential as an individual, and the skills and tools to thrive.

    • Undergraduate courses
    • Graduate courses
    • Short courses
    • Study abroad
    • Centre for Languages & International Education
  • Research
    Tree-of-Life-MehmetDavrandi-UCL-EastmanDentalInstitute-042_2017-18-800x500-withborder (1)
    Research at UCL

    Find out more about what makes UCL research world-leading, how to access UCL expertise, and teams in the Office of the Vice-Provost (Research, Innovation and Global Engagement).

    • Engage with us
    • Explore our Research
    • Initiatives and networks
    • Research news
  • Engage
    UCL Print room
    Engage with UCL

    Discover the many ways you can connect with UCL, and how we work with industry, government and not-for-profit organisations to tackle tough challenges.

    • Alumni
    • Business partnerships and collaboration
    • Global engagement
    • News and Media relations
    • Public Policy
    • Schools and priority groups
    • Visit us
  • About
    UCL welcome quad
    About UCL

    Founded in 1826 in the heart of London, UCL is London's leading multidisciplinary university, with more than 16,000 staff and 50,000 students from 150 different countries.

    • Who we are
    • Faculties
    • Governance
    • President and Provost
    • Strategy
  • Active parent page: Brain Sciences
    • Study
    • Research
    • About the Faculty
    • Institutes and Divisions
    • Active parent page: News and Events
    • Contact

Landmark study tests whether immunotherapy drugs can prevent onset of symptoms in patients at high risk of developing Alzheimer’s

Breadcrumb trail

  • Brain Sciences
  • News and Events

Faculty menu

  • Current page: Faculty news
  • Events

The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) is an international collaboration working with 200 people who are at high risk of developing early onset Alzheimer's disease. These patients have a 50 per cent chance of carrying a rare genetic mutation which would see them develop dementia early in life, around their 30s or 40s.

The UK arm of the study is being led by Dr Cath Mummery, consultant neurologist at UCLH's National Hospital for Neurology and Neurosurgery (NHNN) and head of clinical trials at Queen Square’s Dementia Research Centre, UCL Institute of Neurology.

These patients know that they may get Alzheimer's disease because they may have a mutation that causes it, but they don't have symptoms. So we're trying to prevent the onset of the disease, which is very different from studies so far that have trialled treatments in those already suffering from dementia. Dr Cath Mummery

These patients know that they may get Alzheimer's disease because they may have a mutation that causes it, but they don't have symptoms. So we're trying to prevent the onset of the disease, which is very different from studies so far that have trialled treatments in those already suffering from dementia. Dr Cath Mummery

The research team working at the Leonard Wolfson Experimental Neurology Centre at Queen Square monitors participants closely for signs of Alzheimer’s developing, before symptom onset, looking at imaging changes in the brain, cognitive performance and spinal fluid.Sophie Leggett, from Suffolk, is participating in the study. Her aunt and her mother developed Alzheimer's in their early 40s.

Now 39, she has chosen not to know whether she has the genetic mutation that could lead to the illness.

She wants more research to tackle what has become one of the biggest health challenges of a generation. She is worried if she has the mutation, it could be passed on to her own daughter.

I can cope with the possibility that it could happen to me. And I have many a time made a deal with God saying I'll take it, give it to me, but don't let my daughter have it. I think we all want to protect our children. And I don't want her to feel the fear that I feel now for myself. Sophie Leggett, trial participant

If the therapies are successful the benefits could extend to people beyond this patient group, said Dr Mummery.

The really exciting bit is - potentially - we can extrapolate to that larger Alzheimer’s population and potentially start to look at using this treatment for preventative measures for them. Dr Cath Mummery

Dr Mummery is supported by the NIHR Biomedical Research Unit at University College London Hospitals NHS Foundation Trust and University College London.

Further information:

  • DIAN-TU website
  • Dementia Research Centre, UCL Institute of Neurology
  • Leonard Wolfson Experimental Neurology Centre
  • NIHR Biomedical Research Centre
  • Dr Cath Mummery's profile
  • IoN news item on DIAN-TU launch

Image: Sophie Leggett, 39, is part of the first UK trial to see if Alzheimer's symptoms can be prevented

UCL footer

Visit

  • Bloomsbury Theatre and Studio
  • Library, Museums and Collections
  • UCL Maps
  • UCL Shop
  • Contact UCL

Students

  • Accommodation
  • Current Students
  • Moodle
  • Students' Union

Staff

  • Inside UCL
  • Staff Intranet
  • Work at UCL
  • Human Resources

UCL social media menu

  • Link to Soundcloud
  • Link to Flickr
  • Link to TikTok
  • Link to Youtube
  • Link to Instagram
  • Link to Facebook
  • Link to Twitter

University College London, Gower Street, London, WC1E 6BT

Tel: +44 (0) 20 7679 2000

© 2025 UCL

Essential

  • Disclaimer
  • Freedom of Information
  • Accessibility
  • Cookies
  • Privacy
  • Slavery statement
  • Log in